Bariatric Surgery
60 articles on Bariatric Surgery, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly Prepares FDA Run for ‘Triple-G’ Weight Loss Drug With Phase 3 Data
Eli Lilly has announced positive Phase 3 results for retatrutide, positioning the triple-agonist drug for an FDA filing in 2027 with substantial weight loss outcomes.
7 min read
Millions Losing Weight Using GLP-1s: How Do Drugs Affect Love Lives?
As millions turn to GLP-1 medications for weight loss, unexpected changes in romantic relationships and sexual desire are emerging. This article explores the psychological and physiological impacts on love lives.
6 min read
Ozempic Face and Hair Loss: Evidence for GLP-1 Drug Side Effects
Weight-loss medications like Wegovy and Mounjaro have surged in popularity, leading to increased discussions about their side effects. This article delves into the scientific evidence for frequently reported concerns such as 'Ozempic face,' hair thinning, digestive problems, and eye conditions associated with GLP-1 agonists.
11 min read
Eli Lilly to Seek FDA Approval for Obesity Drug Retatrutide
Eli Lilly announces plans to file for FDA approval of its triple-agonist obesity drug retatrutide in early 2027 following successful Phase 3 trial data.
8 min read
GLP-1s for Teen Weight Loss: A New Treatment Trend?
GLP-1 medications are rapidly changing obesity care for teens and young adults, with a notable shift away from bariatric surgery. This article delves into the latest research, potential benefits, and important considerations for this emerging trend.
7 min read
The Overlooked Nutrition Risks of Ozempic and Wegovy
New research from UCL and Cambridge highlights critical nutrition gaps in GLP-1 therapy. Discover the risks of muscle loss and deficiencies, and how to manage them safely.
8 min read
Bariatric Surgery Shows 5x More Weight Loss Than GLP-1s in Real-World Study
A groundbreaking real-world comparison study presented at the ASMBS 2025 Annual Scientific Meeting found that bariatric surgery resulted in approximately five times more weight loss compared to popular GLP-1 receptor agonist medications over a two-year period. This research highlights important considerations for patients and healthcare providers navigating weight management options.
7 min read
Mounjaro's Impact on Food Cravings: A Case Study
A groundbreaking case study involving deep brain activity recordings has shed light on how tirzepatide, known as Mounjaro and Zepbound, impacts the brain's reward center and its connection to food cravings and loss of control eating.
8 min read
The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
6 min read
GLP-1 Medications for Obesity: Experts See a Broader Revolution Ahead
While GLP-1 receptor agonists have significantly advanced obesity treatment, specialists highlight the evolving landscape of comprehensive, personalized care that integrates various therapeutic strategies.
6 min read
Beyond the Jab: A Natural Weight Loss Journey and Its Hidden Costs
Melanie Sivier chose the 'hard way' over bariatric surgery or new GLP-1 medications like Ozempic and Mounjaro, shedding nine dress sizes through dedication. Her story highlights the profound commitment required for sustainable change, and the often-overlooked physical aftermath.
6 min read
Beyond the Jab: One Woman's Journey to 9-Stone Weight Loss
Melanie Sivier shares her remarkable 9-stone weight loss journey, opting for a dedicated lifestyle change over medical interventions like gastric bands and newer GLP-1 agonists.
6 min read
Ozempic, Wegovy, Mounjaro: How Do They Affect Mental Health?
New research sheds light on the neuropsychiatric effects of popular weight loss medications like semaglutide and tirzepatide. Discover how these treatments may influence anxiety, depression, and other mental health outcomes.
7 min read
Beyond the Hype: Why Some Aren't Responding to GLP-1 Weight Loss Drugs
While GLP-1 agonists have revolutionized weight loss for many, a significant portion of individuals don't experience the same dramatic results. This article delves into the reasons behind GLP-1 non-response and offers guidance for those seeking effective weight management solutions.
7 min read
Semaglutide and Male Fertility: New Study Reveals Testosterone Boost
Can GLP-1 medications like Ozempic or Wegovy improve male fertility? A new study indicates potential benefits for testosterone and sperm health, but what does this mean for patients?
7 min read
Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds
A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.
7 min read
Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?
Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.
8 min read
Beyond BMI: Hidden Health Reasons Doctors May Decline Mounjaro or Wegovy
While BMI is a primary factor, a range of underlying health conditions and personal histories can lead to a doctor declining a prescription for popular weight loss medications like Mounjaro and Wegovy. Understanding these criteria is vital before seeking treatment.
7 min read
Beyond the Scale: Unpacking the 'Darth Vader' Effect of Rapid Weight Loss
A peculiar new side effect, dubbed the 'Darth Vader' effect, is emerging with rapid weight loss achieved through GLP-1 medications. This article delves into the phenomenon, its potential causes, and the critical need for a balanced approach to weight management.
7 min read
Retatrutide: The Next Frontier in Weight Loss and Its Profound Implications
Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.
7 min read
Retatrutide's Rapid Weight Loss: Balancing Benefits and Risks
New-generation GLP-1 drugs like retatrutide promise unprecedented weight loss, but what are the implications for your body's composition and overall health? This article delves into the science, risks, and strategies for navigating rapid weight reduction.
8 min read
Retatrutide Breakthrough: Can This Molecule Rival Gastric Bypass Surgery?
New data suggests Eli Lilly's retatrutide could deliver up to 28% weight loss, potentially rivaling bariatric surgery. Learn about efficacy and safety.
8 min read
Retatrutide Breaks Records: What Phase 3 TRIUMPH-1 Data Means
Eli Lilly's Retatrutide has shown remarkable weight loss potential in Phase 3 trials. We break down the TRIUMPH-1 results, safety data, and what patients can expect.
9 min read
Retatrutide: A New Era in Weight Loss Drugs vs. Ozempic
Eli Lilly's experimental drug retatrutide has demonstrated unprecedented weight loss results in a pivotal trial. This article delves into its mechanisms, efficacy, safety, and how it stacks up against current leading weight loss medications like Ozempic and Wegovy.
6 min read
Retatrutide: Eli Lilly's New Drug Challenges Ozempic in Weight Loss
Eli Lilly's experimental drug Retatrutide is making waves with unprecedented weight loss results in clinical trials, potentially setting a new benchmark in obesity treatment. This comprehensive look examines its efficacy, mechanism, and comparison to existing GLP-1 and GIP agonists.
8 min read
GLP-1 Drugs vs. Weight Loss Surgery: A Shifting Landscape
New research indicates a significant decline in bariatric surgeries, coinciding with the rise of GLP-1 medications. This article delves into the implications, comparing the efficacy and cost-effectiveness of these treatments and offering guidance for patients.
7 min read
GLP-1 Slimming Drugs Boom Sparks Misuse Concerns in India
The surge in GLP-1 weight-loss injections like semaglutide in India, fueled by prices dropping up to 90%, is alarming doctors amid rising cosmetic misuse by young women. Social media and wedding pressures are pushing unsupervised use, risking serious side effects. Experts stress these are prescription therapies for obesity, not quick fixes.
5 min read
Men Coined 'Looksmaxxing,' Women Invented It: Trends & Risks
Looksmaxxing started in incel circles but mirrors women's long history of extreme beauty pursuits, from plastic surgery to Ozempic weight loss. Radical tactics like bone-smashing and crystal meth highlight its dangers, while celebrity denials fuel uncanny reactions. Unpack the cultural shift pushing men into fraught body modification.
7 min read
Safely Buy GLP-1 Drugs Online: Key Facts Amid Ad Surge
Serena Williams' 2026 Super Bowl ad spotlighted her GLP-1 weight-loss journey, fueling massive online searches for drugs like Ozempic and Wegovy. With ads bombarding daily life and insurance often falling short, a booming online market offers cheaper options—but at what risk? Here's what you need to know to safely buy GLP-1 drugs online.
5 min read
Why Mounjaro is Having a Moment: Content Creator's Weight Loss Story
Content creator Aishwarya Mohanraj's candid video about dropping from 74kg to 52kg in six months on Mounjaro has spotlighted the injectable drug. Amid PCOS and hypothyroidism challenges, her story shifts focus from Ozempic hype. But experts warn: pair it with lifestyle changes or risk weight regain.
5 min read
New GLP-1 Playbook for Weight Loss: Shots to Pills Shift
Weight loss treatment is evolving with a new GLP-1 playbook: start with weekly injections for rapid results, then transition to convenient pills for maintenance. Eli Lilly's weight-loss tablet and oral Wegovy promise easier adherence, but with trade-offs in effectiveness and strict dosing rules. Doctors highlight the maintenance challenges that make this shift essential.
6 min read
GLP-1s Benefit Non-Responders Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
5 min read
Ozempic Isn't a Magic Fix: Semaglutide Risks in India
Semaglutide injections like Ozempic have arrived in India at low prices, exciting millions with diabetes and rising obesity. But experts like Dr. Gagandeep Singh caution it's no magic fix—weight returns upon stopping, muscle loss is common, and misuse risks malnutrition. Understand the real story behind these GLP-1 weight loss injections.
6 min read
Heather Gay's Ozempic Weight Loss Journey: RHOSLC Star's Transformation
Real Housewives of Salt Lake City star Heather Gay has shared her Ozempic-assisted weight loss journey, crediting the GLP-1 injection for noticeable results after initial slow progress. Losing around 30 pounds amid social pressures from friends' transformations, she called it a 'long, overdue glow-up' thanks to modern medicine. Despite Ozempic face rumors, Gay remains open about her experience.
4 min read
23andMe Study: Genetic Changes Predict GLP-1 Response for Weight Loss
A groundbreaking 23andMe study published in Nature identifies specific genetic changes in two genes that predict how well patients respond to GLP-1 drugs for weight loss—and whether they'll experience common side effects like nausea or vomiting. Led by Adam Auton, the research offers proof of concept for genetics in GLP-1 therapy. While experts are intrigued, questions remain on clinical impact.
4 min read
Ozempic Users Warned: Don't Skip Exercise, Study Urges
Ozempic users who skip exercise face suboptimal results, according to a new study in Sports Medicine on GLP-1 drugs like Victoza and Saxenda. Among 193 adults, those combining medication with structured workouts saw the best outcomes, while sedentary users fared worst. Meanwhile, one patient's rare blindness side effect highlights ongoing risks.
5 min read
Study Warns Ozempic May Double Divorce Risk in Couples
Rapid weight loss from procedures like gastric band surgery may double divorce rates, per a Swedish study—and experts warn Ozempic could trigger similar relationship strains. Professor Per-Arne Svensson highlights how newfound confidence and lifestyle shifts might lead to breakups. Discover the full implications for couples eyeing GLP-1 medications.
5 min read
Doctors Warn: Wedding Weight-Loss Jabs Cause 'Ozempic Face'
Young people are turning to semaglutide and tirzepatide for rapid weight loss before weddings, but doctors warn of 'Ozempic face'—a gaunt, prematurely aged appearance from excessive facial fat and muscle loss. Experts like Dr. Ajaya Kashyap share real cases requiring corrective treatments. Understand the trend, risks, and why medical supervision is essential.
6 min read
Ozempic Hair Loss: Doctors Explain the Real Causes
Ozempic users are reporting more hair in brushes and showers, sparking fears of direct drug damage. But doctors like bariatric surgeon Dr. Neha Shah explain it's mainly from rapid weight loss triggering telogen effluvium. With proper nutrition and care, most see full recovery within months.
5 min read
GLP-1 Weight-Loss Drugs Face Bone Health Risks in Older Adults
Emerging research is raising questions about GLP-1 weight-loss drugs like Ozempic and Wegovy, showing a potential link to bone loss and fractures in older adults. A major study in the Journal of Clinical Endocrinology & Metabolism found higher fragility fracture risks among seniors on these medications. Experts stress monitoring and preventive steps to balance benefits with bone protection.
5 min read
JD Vance Sparks Ozempic Rumors With Slimmer Appearance
Vice President JD Vance appeared noticeably slimmer in a recent interview with Benny Johnson, igniting Ozempic rumors across X. Netizens speculate on the popular weight-loss drug amid past denials and critic backlash. While no confirmation exists, the buzz highlights Ozempic's role in metabolic health conversations.
5 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
5 min read
Dr. Trehan Warns: Generic GLP-1 Drugs Shouldn't Be OTC
As generic GLP-1 drugs flood the Indian market post-patent expiry, Dr. Naresh Trehan warns they shouldn't be available over-the-counter due to serious side effects. Government advisories stress medical supervision to prevent misuse. Experts like Dr. Gupta and Dr. Bhattacharya highlight risks of self-medication with semaglutide and liraglutide.
6 min read
'Ozempic Teeth': Dentists Urge Awareness of Weight Loss Drug Oral Risks
Weight loss drugs like Ozempic are transforming bodies, but dentists are sounding the alarm on 'Ozempic teeth'—a pattern of dry mouth, tooth sensitivity, and gum problems. Lt. Gen Dr Vimal Arora of Clove Dental notes increased xerostomia, dental caries, and early periodontal inflammation among users. Discover why this happens and steps to safeguard your smile.
4 min read
GLP-1 Drugs Surge: Healthy Habits Still Essential for Best Results
Demand for GLP-1 drugs like Wegovy and Zepbound is booming, with 1 in 8 Americans now using them. But experts warn: medication alone isn't enough—pairing with healthy habits like protein-rich meals, exercise, and sleep amplifies weight loss and health gains, per recent studies.
6 min read
Study: 10% of Wegovy and Ozempic Users See Minimal Weight Loss
Recent trials show about 10% of people using Wegovy and Ozempic experience minimal weight loss, classified as 'non-responders.' Despite average reductions of 15-20%, stories like Samantha Jess's highlight real challenges. Discover why GLP-1 drugs don't work for everyone and how to optimize results.
5 min read
ARD-201 Trial: Maintaining Weight Loss After Ozempic, Wegovy
GLP-1 drugs like Ozempic and Wegovy deliver impressive weight loss, but regain is common after stopping. A new Phase 2 trial of oral ARD-201 aims to change that by regulating appetite via bitter taste receptors. Led by obesity expert Lawrence Cheskin at George Mason University, this study targets post-treatment weight maintenance.
5 min read
Ozempic's Impact on Gay Men's Body Image and Bottoming
Ozempic and other GLP-1 medications promise weight loss and health gains, but they're fueling toxic body image problems in the gay community. Queer celebs like Margaret Cho and Boy George are praising the drugs, yet experts highlight risks to body confidence and even the ability to bottom. No studies yet focus on LGBTQ+ users, but the impacts are real.
5 min read
Boston Unions Fire Back at Wu's GLP-1 Coverage Ultimatum
Boston Public Employee Committee rejects Mayor Wu's push for immediate prior authorization on GLP-1 weight loss drugs, proposing a six-month delay instead. Amid skyrocketing costs projected at $47.4M for FY27, unions demand a contract extension. Tensions rise as some unions favor cuts to avoid layoffs.
5 min read
Low-Cost Semaglutide Generics Coming to India as Patent Expires
India's Semaglutide patent expires March 20, opening doors for low-cost generics from pharma giants like Zydus, Torrent, Sun Pharma, and Dr. Reddy's. With over 23% of women and 22% of men overweight per NFHS-5, and 45 crore adults projected obese by 2050, affordable options could reshape the fight against obesity and diabetes. Discover the price revolution and challenges ahead.
5 min read
MGB's New Genetic Risk Calculator for Obesity: A Game Changer
Researchers at Mass General Brigham have launched a revolutionary genetic risk calculator that not only forecasts obesity and Type 2 diabetes but also their long-term health consequences. Powered by data from over 8.5 million participants worldwide, this polygenic risk score outperforms existing tools, especially in diverse populations. Discover why this could enable earlier interventions like GLP-1 medications.
5 min read
GLP-1 Discontinuation: Mixed Weight Loss Results in Real-World Study
A large real-world study from Cleveland Clinic reveals mixed outcomes after GLP-1 discontinuation: 55% of obese patients regained weight, while 45% maintained or continued losing. Many switched to alternative treatments, highlighting the need for ongoing obesity care. This data underscores gaps in long-term management and the role of nutritional support.
5 min read
Melissa McCarthy Oscars Pics Spark Ozempic Face Rumors
Melissa McCarthy turned heads at the 2026 Oscars in a stunning gown, but her noticeably slimmer face reignited Ozempic rumors. Side-by-side pics with her 2012 Oscars appearance make the change crystal clear. Onstage, she even poked fun at the speculation during a Bridesmaids reunion.
4 min read
Novo Nordisk Expands Ozempic, Wegovy Testing on Adolescents
Novo Nordisk, maker of Ozempic and Wegovy, has launched a three-year research partnership to test weight-loss GLP-1 drugs on adolescents in Pacific Island nations, beginning in Fiji. Announced amid a Danish royal visit, this move addresses the obesity 'ticking bomb' threatening kids' lifespans. CEO Mike Doustdar urges bolder action on prevention and access.
5 min read
Ozempic at Oscars 2026 Red Carpet: Is Skinny Back?
At the Oscars 2026 red carpet, an overwhelming uniformity of extremely slender bodies and sunken cheeks dominated, raising questions about Ozempic and GLP-1 agonists. Celebrities like Demi Moore, Emma Stone, and Oprah Winfrey appeared dramatically thinner, contrasting the body positivity era. Is Hollywood reverting to 'heroin chic' aesthetics?
5 min read
Ozempic Causes Fast Weight Loss, But Also Muscle Loss: Study Insights
Revolutionary GLP-1 medications like Ozempic are helping millions shed pounds quickly, but a new study shows significant muscle loss is a downside. Experts warn that up to 40% of weight lost can be lean tissue, especially with rapid drops. Here's how to protect your muscle while benefiting from these drugs.
6 min read
Quitting Ozempic? What Happens When You Stop: Weight Regain & Risks
Stopping Ozempic can lead to full weight regain in about 1.7 years, plus reversal of cardiovascular and metabolic benefits, warns a major BMJ review. Nearly 50% of users discontinue within a year due to side effects and high costs. Doctors urge consulting before quitting to protect your health gains.
5 min read
Stylists Fear Hollywood Stars Blind to Extreme Thinness from Ozempic Microdosing
This awards season, Hollywood red carpets showcase pin-thin silhouettes from Emma Stone to Jenna Ortega, fueled by Ozempic microdosing. Stylists fear stars are unaware of their extreme thinness, while nutritionists spot muscle wasting and malnutrition signs. As body positivity fades, insiders reveal the pressure and health toll.
5 min read
When Weight-Loss Drugs Like Zepbound Don't Work
Jessica Layeux spent 15 months on Zepbound with minimal weight loss, joining 1 in 10 clinical trial non-responders who lose less than 5% body weight. Scientists are investigating genetics, hormones, and other factors behind why these popular GLP-1 drugs don't work for everyone. This guide explains the science and next steps for patients.
5 min read
Why Layla Taylor Quit GLP-1s: Mormon Wives Star's Story
Layla Taylor, star of The Secret Lives of Mormon Wives, has stepped away from GLP-1 medications after using them as an unhealthy crutch for her lifelong eating disorder. Ahead of season 4, she opens up about hidden side effects like aching joints, falling hair, and constant fatigue that signaled her body was breaking down. Her story underscores the importance of monitoring GLP-1 use, especially with pre-existing conditions.
6 min read